Delivery Order SPE2DB20D2104-SPE2DB25FMZTA
- Not listed
- The Defense Logistics Agency awarded a $16,252.69 delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 mL pens on August 22, 2025, with an ultimate completion date of August 25, 2025. This non-set-aside, firm fixed price contract represents a small-value transaction within AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The award is performed from the vendor's Conshohocken, Pennsylvania location, the company's corporate headquarters....
- The Defense Logistics Agency awarded a $5,001.99 firm fixed-price delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 mL pens on July 18, 2025, with an ultimate completion date of July 21, 2025. This non-set-aside contract represents a delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through December 2026. The pharmaceutical product will be delivered to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 4,569,036,577 units of DUPIXENT 300 MG/2 ML pens (2 ML vials) valued at $5,656.54 with a firm fixed price structure. The award was made on August 8, 2025, with an ultimate completion date of August 11, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this delivery from its Corporate Office location, consistent...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,706.66 to AmerisourceBergen Drug Corp for the supply of DUPIXENT 300 MG/2 ML PEN 2ML, with an ultimate completion date of September 9, 2025. This firm fixed-price, competitively awarded contract contains no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 ml pen injectors, valued at $6,777.99, with an ultimate completion date of August 15, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a continuation of the company's ongoing pharmaceutical supply relationship with the federal government. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a $6,049.03 delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 mL pens (2 mL units) with a firm fixed price structure and an ultimate completion date of July 28, 2025. This non-set-aside contract was competitively awarded and represents a child order under AmerisourceBergen's broader pharmaceutical supply agreements with the federal government. The order will be fulfilled from the vendor's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $14,397.15 delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 ml pen auto-injectors. The contract, finalized on August 12, 2025, with completion targeted for August 13, 2025, utilizes firm fixed pricing with no set-aside designation, indicating competitive award through open solicitation. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, the company's headquarters. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pen injectors valued at $7,550.30 under a firm fixed price contract. The award was made on July 21, 2025, with an ultimate completion date of July 22, 2025, and represents a non-set-aside competitive award. AmerisourceBergen will perform this work at its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,747.93 to AmerisourceBergen Drug Corp for the supply of DUPIXENT 300 mg/2 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of September 3, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform at its corporate office location. This delivery order falls under the company's broader...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the provision of DUPIXENT 300 MG/2 ML PEN 2ML pharmaceutical products. The contract, valued at $6,609.40, has an ultimate completion date of April 11, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to AmerisourceBergen Drug Corp by DLA, valued up to $999,999,999.00 with a...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMZTADelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $147,823.11 to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pens on September 8, 2025, with completion scheduled for September 9, 2025. This firm fixed-price delivery order, issued without a set-aside designation, represents a competitive award to the prime contractor under its existing indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's distribution facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's master IDC with DLA valued at $999,999,999.00 through December 2026, which serves as the primary pharmaceutical supply vehicle for military healthcare systems. AmerisourceBergen, a major pharmaceutical distributor headquartered in Pennsylvania, maintains an extensive portfolio of federal medical contracts and supplies critical medications, vaccines, and medical devices to support Defense Health Agency and other government healthcare systems worldwide. The DUPIXENT product delivery supports military medical supply chain requirements for this specialty medication used in treating various inflammatory conditions across the DoD healthcare enterprise.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $147.8k | 9/8/25 |